C-TAP, part of the Solidarity call to action, recently announced three licensing agreements via the Medicines Patent Pool (MPP). Launched in 2020 by WHO and Costa Rica with support from various stakeholders, C-TAP serves as a platform for sharing intellectual property, knowledge, and data among developers of COVID-19 therapeutics, diagnostics, vaccines, and health products. MPP, a UN-backed organization, collaborates with diverse partners to enhance access to life-saving medicines in low- and middle-income nations. By pooling intellectual property and promoting generic manufacturing, MPP aids in medication development and affordability.
Facts/Terms for UPSC Prelims
- Solidarity Call to Action: A global initiative promoting collaboration and resource-sharing among stakeholders to combat the COVID-19 pandemic, of which C-TAP is a part.
- Generic Manufacture: The production of medicines by companies other than the original patent holder, often resulting in lower-priced alternatives, crucial for improving accessibility.
- Intellectual Property: Legal rights granted to creators or inventors, which C-TAP encourages developers to share to facilitate wider access to COVID-19 solutions.
- Medication Formulations: Refers to different versions or preparations of medicines, including dosage forms, which may be important for tailoring treatments to specific patient needs.
